Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494766 · ClinicalTrials.gov registry record · NA
Efficacy of Tyrosine in Restless Legs Syndrome
A NA study, sponsored by Seton Healthcare Family.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01494766: Completed NA study, sponsored by Seton Healthcare Family.
NCT01494766 is a NA study that has completed, run by Seton Healthcare Family. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01494766, a NA study, has completed, sponsored by Seton Healthcare Family.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine. It is well known that dopamine deficiency leads to the manifestations of restless legs syndrome (RLS). Studies have shown dopamine agonists and L-dopa to be effective in controlling symptoms. No studies to date have been done to determine the role of tyrosine in RLS. This open-label pilot study aims to determine the efficacy and tolerability of tyrosine in RLS, as current agents have limitations in treating RLS in addition to adding another possible agent to the investigators arsenal of treating RLS that maybe more cost efficient. In this pilot study, the dose of tyrosine will be escalated from 750 mg once daily by mouth (PO) up to 3000 mg once daily PO, as tolerated, in increments of 750 mg every week in patients who meet the inclusion criteria for RLS. Patients' symptoms will be monitored on a weekly basis for six weeks.
Primary Outcome
Use of this survey to be used as a marker for severity of RLS symptoms and therefore efficacy of this medication.
Interventions
- DIETARY_SUPPLEMENT L-Tyrosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-11 |
| Phase | NA |
What the finished NCT01494766 record still lists
NCT01494766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which L-Tyrosine is the first listed.
NCT01494766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01494766 about?
NCT01494766 is a clinical study titled "Efficacy of Tyrosine in Restless Legs Syndrome". Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine. It is well known that dopamine deficiency leads to the manifestations of restles...
What is the current status of trial NCT01494766?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2012-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01494766?
The interventions under investigation include: L-Tyrosine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01494766?
This trial is sponsored by Seton Healthcare Family, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01494766's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia